Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients

Journal of Women's Health

Volumn 22, Issue 2, 2013, Pages 113-120

  Maskew, Mhairi ^a,b   Brennan, Alana T ^c   Westreich, Daniel ^d   McNamara, Lynne ^a,b   MacPhail, A Patrick ^b,e   Fox, Matthew P ^a,c  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d IL   (United States)

^e RIGHT TO CARE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; HEMOGLOBIN; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SOUTH AFRICA; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADOLESCENT; ADULT; AGE FACTORS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SOCIOECONOMIC FACTORS; SOUTH AFRICA; TIME FACTORS; TREATMENT OUTCOME; URBAN POPULATION; VIRAL LOAD; YOUNG ADULT;

EID: 84873632715     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2012.3585     Document Type: Article

References (55)

1. Bendavid E, Bhattacharya J. The President's Emergency Plan for AIDS Relief in Africa, an evaluation of outcomes. Ann Intern Med 2009;150:688-695.
2. Jensen-Fangel S, Pedersen L, Pedersen C, et al. Low mortality in HIV-infected patients starting highly active antiretroviral therapy, a comparison with the general population. AIDS 2004;18:89-97. (Pubitemid 38402322)
3. Keiser O, Orrell C, Egger M, et al. Public-health and individual approaches to antiretroviral therapy, Township South Africa and Switzerland compared. PLoS Med 2008;5:e195.
4. Akileswaran C, Lurie MN, Flanagin TP, et al. Lessons learned from the use of highly active antiretroviral therapy in Africa. Clin Infect Dis 2005;41:376-385. (Pubitemid 41022117)
5. Nash D, Katyal M, Brinkhof M, et al. Long-term immuno-logic response to antiretroviral therapy in low-income countries, a collaborative analysis of prospective studies. AIDS 2008;22:2291-2302.
6. The ART-LINC Collaboration and ART-CC groups. Mortality of HIV-1-infected patients in the first year of an-tiretroviral therapy, comparison between low-income and high-income countries. Lancet 2006;367:817-824.
7. Ivers L, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings, a meta-analysis of the published literature. Clin Infect Dis 2005;41:217-224. (Pubitemid 40962502)
8. Giordano T, Wright J, Hasan M, et al. Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin Infect Dis 2003;37:433-437. (Pubitemid 36976503)
9. Maman D, Pujades-Rodriguez M, Subtil F, et al. Gender differences in immune reconstitution: A multicentric cohort analysis in sub-Saharan Africa. PLoS One 2012;7:e31078.
10. Chêne G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy, analysis of prospective studies. Lancet 2003;362:679-686.
11. Carrieri MP, Raffi F, Lewden C, et al. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virologic response, a 3-year follow-up study. An-tivir Ther 2003;8:585-594. (Pubitemid 38057104)
12. Lawn S, Harries A, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008;22:1897-1908.
13. UNAIDS. Global Report. UNAIDS Report on the Global AIDS Epidemic. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS), 2010.
14. Mocoft A, Gill MJ, Davidson W, et al. Are there gender differences in starting protease inhibitors, HAART and disease progression despite equal access to care? J AIDS 2000; 24:475-482.
15. Moore AL, Kirk O, Johnson AM, et al. Virologic, immu-nologic and clinical response to highly active antiretroviral therapy, the gender issue revisited. J AIDS 2003;32:452-461. (Pubitemid 36363161)
16. Moore AL, Sabin CA, Johnson MA, et al. Gender and clinical outcomes after starting highly active antiretroviral treatment, a cohort study. J AIDS 2002;29:197-202. (Pubitemid 34164894)
17. Lemly D, Shepherd B, Hulgan T, et al. Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis 2009;19:991-998.
18. Napravnik S, Poole C, Thomas J, et al. Gender difference in HIV RNA levels,a meta-analysis of published studies. J AIDS 2002;31:11-19.
19. Floris-Moore M, Lo Y, Klein RS, et al. Gender and hospitalisation patterns among HIV-infected drug users before and after the availability of highly active antiretroviral therapy. J AIDS 2003;34:331-337. (Pubitemid 37377369)
20. Cornell M, Myer L, Kaplan R, et al. The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Trop Med Int Health 2009;14:722-731.
21. Kumarasamy N, Venkatesh K, Cecelia A, et al. Gender-based differences in treatment and outcome among HIV patients in South India. J Womens Health 2008;17:1471-1475.
22. National Department of Health. National antiretroviral treatment guidelines, 1st ed. 2004. Available at www.doh.gov.za/docs/factsheets/ guidelines/artguide04-f.html Accessed July 20, 2009.
23. Black V, Hoffman R, Sugar C. Safety and efficacy of initiating highly active antiretroviral therapy in an integrated antenatal and HIV clinic in Johannesburg, South Africa. J AIDS 2008;49:276-281.
24. Boulle A, Van Cutsem G, Hilderbrand K, et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 2012;24:563-572.
25. Fairall LR, Bachmann MO, Louwagie GM, et al. Effectiveness of antiretroviral treatment in a South African program: A cohort study. Arch Intern Med 2008;168:86-93.
26. Fox MP, Brennan AB, Maskew M, et al. Using vital registration data to update mortality among patients lost to follow-up from ART programmes: Evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health 2012;15:405-413.
27. Herna'n MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000;11:561-570. (Pubitemid 30660035)
28. Cole SR, Herna'n MA. Constructing inverse probability weights for marginal structural models. Am. J Epidemiol 2008;168:656-664.
29. Robins JM, Finkelstein. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 2000;56:779-788.
30. Wools-Kaloustian K, Kimaiyo S, Diero L, et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa, experience from western Kenya. AIDS 2006;20:41-48. (Pubitemid 41818113)
31. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006;20:1391-1399.
32. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001;15: 1115-1123. (Pubitemid 32549862)
33. Moore J, Schuman P, Schoenbaum E, et al. Severe adverse life events and depressive symptoms among women with, or at risk for, HIV infection in four cities in the United States of America. AIDS 1999;13:2459-2468.
34. Friedland GH, Saltzman B, Vileno J, et al. Survival differences in patients with AIDS. J AIDS 1991;4:144-153.
35. Stein MD, Piette J, Mor V, et al. Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons. J Gen Intern Med 1991;6:35-39.
36. Bozzette SA, Berry SH, Duan N, et al. The care of HIV-infected adults in the United States. N Engl J Med 1998;339: 897-1904.
37. Carpenter CC, Mayer KH, Stein MD, et al. Human immunodeficiency virus infection in North American women: Experience with 200 cases and a review of the literature. Medicine 1991;60:307-325.
38. Minkoff HL, Willoughby A, Mendez H, et al. Serious infections during pregnancy among women with advanced human immunodeficiency virus infection. Am J Obstet Gy-necol 1990;162:30-34. (Pubitemid 20055415)
39. Justice AC, Feinstein AR, Wells CK. A new prognostic staging system for the acquired immunodeficiency syndrome. N Engl J Med 1889;320:1388-1393.
40. Clark RA, Blakley SA, Rice J, et al. Predictors of HIV disease progression in women. J AIDS 1994;9:43-50.
41. Braitstein P, Boulle A, Nash D, et al. Gender and use of antiretroviral treatment in resource-constrained settings: Findings from a multicenter collaboration. J Womens Health 2008;17:47-55. (Pubitemid 351197536)
42. Nicastri E, Angeletti C, Palmisano L, et al. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS 2005;19:577.
43. Barth R, van der Meer J, Hoepelman A, et al. Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa. Eur J Clin Microbiol Infect Dis 2008;27:977-984.
44. Muula AS, Ngulube TJ, Siziya S, et al. Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa, a systematic review. BMC Public Health 2007;7:1-8.
45. Anastos K, Gange SJ, Lau B, et al. Association of race and gender with HIV-1 RNA levels and immunologic progression. J AIDS 2000;24:218-226.
46. Zachariah R, Fitzgerald M, Massaquoi M, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 2006;20:2355-2360. (Pubitemid 44789538)
47. Maskew M, Menezes C, MacPhail AP, et al. Lost to follow-up-Contributing factors and challenges in South African patients on antiretroviral therapy. S Afr Med J 2007;97:853-857. (Pubitemid 47542654)
48. Weiser S, Wolfe W, Bangsberg D, et al. Barriers to anti-retroviral adherence for patients living with HIV infection and AIDS in Botswana. J AIDS 2003;34;281-288. (Pubitemid 37377361)
49. Sayles JN, Wong MD, Cunningham WE. The inability to take medications openly at home: Does it help explain gender disparities in HAART use? J Womens Health 2006; 15:173-181.
50. Murri R, Lepri AC, Phillips AN, et al. Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex. J AIDS 2003;34:184-190. (Pubitemid 37248915)
51. Kuyper L, Wood E, Montaner J, et al. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-infected patients in a population-based cohort. J AIDS 2004;37:1470-1476. (Pubitemid 39602337)
52. Fish EN. The X-files in immunity: Sex-based differences predispose immune responses. Nat Rev Immunol 2008;8: 737-744.
53. Ruel TD, Zanoni BC, Ssewanyana I, et al. Sex differences in HIV RNA level and CD4 cell percentage during childhood. Clin Infect Dis 2001;53:592-599.
54. Maini MK, Cilson RJC, Chavda N, et al. Reference ranges and sources of variability of CD4 counts in HIV seronegative women and men. Genitourin Med 1996;72:27-31. (Pubitemid 26057871)
55. TollerudD,ClarkJ, Morris Brown L,et al. The influenceofage, race and gender on peripheral blood mononuclear cell subsets in healthy nonsmokers. J Clin Immunol 1989;9: 214-222. (Pubitemid 19162946)